| |
FOR: CARDIOCOMM SOLUTIONS, INC.
TSX VENTURE SYMBOL: EKG
Former Executive of
ScottCare, CardioNet and Lifewatch Corporation
Set to Drive Sales of GEMS? and Mobile Patient
Monitoring Solutions into the U.S. Market
TORONTO, ONTARIO - CardioComm
Solutions, Inc. (TSX VENTURE:EKG)
("CardioComm Solutions" or the "Company") today
announced that Mr. Daniel Pawlik has joined the
organization as Vice President, Sales and
Marketing for the United States effective
January 6, 2014.
Mr. Pawlik has held senior executive positions
within a number of large U.S.-based companies
specializing in electrocardiogram ("ECG")
cardiac monitoring including Vice President of
Sales, Marketing and Business Development U.S.
Diagnostic Field Sales, Technologies and
Contract Services for Ambucor Health Solutions,
Inc., a subsidiary of ScottCare Corporation, and
Vice President, Research Services and
Technologies at LifeWatch Services Inc.
Pawlik was the Founder and CEO of Agility
Centralized Research Services, Inc., a clinical
research-based patient monitoring center
providing telemedicine technology and
operational outsourcing of patient monitoring
for cardiac safety testing, contract project
management, data collection and analysis to the
pharmaceutical, medical device and academic
research community. Agility Research was
acquired initially by Biotel and is now a wholly
owned subsidiary of Philadelphia based
CardioNet, Inc. where Pawlik served as Vice
President, Research Services Agility Centralized
Research Services until recruited by ScottCare
Corporation.
"Dan Pawlik is a welcome addition to the
CardioComm Solutions team," noted Simi Grosman,
a member of the Company's Board of Directors.
"His knowledge of the cardiac monitoring
landscape in the U.S. will allow us to
accelerate our sales and development activities
in 2014 and become a key player in this market.
We will continue to build out the U.S. team
under his leadership."
CardioComm Solutions' entry into the mobile
cardiac telemetry ("MCT") market was announced
last year when it concluded a device integration
and distribution deal with TZ Medical that
brought the two companies into the MCT ECG and
arrhythmia management market. Recently the
Company announced completion of a custom MCT
solution for Raytel Cardiac Monitoring,
heralding the release of an off-the-shelf MCT
software solution anticipated for early 2014.
In addition to adding bench strength to
CardioComm Solutions' management team, Daniel
will be directly responsible for driving sales
of GEMS? and patient monitoring solutions in the
U.S. The cardiac monitoring and cardiac
rhythm management devices market is expected to
grow to $23.3B over the next three years
according to a report by MarketsandMarkets, a
global market research and consulting company
based in the U.S. Pawlik will also leverage his
extensive network to identify HeartCheck? PEN
over-the-counter (OTC) sales and service
opportunities in the U.S. market.
"I am very pleased and excited to be joining the
CardioComm Solutions' leadership team in their
mission to build presence and grow market share
within the U.S. health care market. CardioComm
Solutions has developed an extremely innovative,
flexible and effective patient monitoring and
data management system in the GEMS? software
technology platform. The GEMS? technology design
and the capability of the Company's development
team will enable our introduction of a
considerable number of innovative sales and
service solutions that will help providers lower
clinical costs, improve operational efficiencies
and patient care while increasing service
revenues," said Daniel Pawlik. "I am confident
CardioComm Solutions will be a welcomed
technology partner to many health care
organizations."
"We are very pleased to welcome Dan to the
CardioComm Solutions team," said Etienne Grima,
CardioComm Solutions' CEO. "Dan has over 20
years of experience in the medical device and
clinical research industry where he was
responsible for the restructure of sales,
marketing and business development operations,
the integration of contract research services
and development of large sales forces to support
business expansion across the United States.
Dan's priorities will include driving the launch
of our GEMS? 4 product and MCT software as well
as to assist in establishing new technology and
service revenue streams from strategic
partnerships with independent diagnostic testing
facilities, health care providers and increasing
HeartCheck? related service revenues."
download pdf 
CardioComm Solutions' patented and proprietary
technology is used in products for recording,
viewing, analyzing and storing
electrocardiograms (ECGs) for diagnosis and
management of cardiac patients. Products
are sold worldwide through a combination of an
external distribution network and a North
American-based sales team. The Company has
earned the ISO 13485 certification, is HPB
approved, HIPAA compliant, and has received FDA
market clearance for its software devices.
CardioComm Solutions is headquartered in
Toronto, Canada, with offices in Victoria,
B.C.
FOR FURTHER
INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425
investorrelations@cardiocommsolutions.com
www.cardiocommsolutions.com
Forward-looking
statements
This release may contain certain forward-looking
statements with respect to the financial
condition, results of operations and business of
CardioComm Solutions and certain of the plans
and objectives of CardioComm Solutions with
respect to these items. By their nature,
forward-looking statements involve risk and
uncertainty because they relate to events and
depend on circumstances that will occur in the
future and there are many factors that could
cause actual results and developments to differ
materially from those expressed or implied by
these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in
policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of
this release.
|
|
